| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/03/2005 | US20050027011 Preparing a solution of paroxetine hydrochloride and a water-soluble polymer dissolved in a cosolvent of a volatile organic solvent and water, and drying to form amorphous paroxetine hydrochloride in a water soluble matrix; nonhygroscopic; oral dosage forms |
| 02/03/2005 | US20050026996 A taxane such as paclitaxel or docetaxel joined by a hydrolyzable bond to one or more oligomers having a polyethylene glycol moiety; amphiphilic drug conjugate with improved water solubility without drastic increase in molecular weight |
| 02/03/2005 | US20050026995 anticarcinogenic agents comprising a mixture of taxol, solubilizers, stabilizers and anhydrous ethanol, having superior solubility, stability, bioavailability and side effect reduction |
| 02/03/2005 | US20050026992 Treatment and prevention of cardiovascular events |
| 02/03/2005 | US20050026981 Stable oral solid drug composition |
| 02/03/2005 | US20050026958 Methods of therapeutic treatment using amounts of retinoid components |
| 02/03/2005 | US20050026948 Inflammatory and/or obstructive respiratory tract disorders |
| 02/03/2005 | US20050026924 Compositions containing alpha-2-adrenergic agonist components |
| 02/03/2005 | US20050026887 Anticholinergic is a 1-(3-phenoxypropyl)-3-((2-hydroxy-2,2-bisthien-2-yl)acetoxy)quinuclidinium salt of given formula and steroid such as fluticasone; kit with dosage forms and instructions; treating allergic or non-allergic rhinitis |
| 02/03/2005 | US20050026886 Phosphodiesterase IV (PDE IV) inhibitor such as roflumilast or cilomilast with a 1-(3-phenoxypropyl)-3-((2-hydroxy-2,2-bisthien-2-yl)acetoxy)quinuclidinium salt of given formula; kit with dosage forms and instructions; treating inflammatory or obstructive respiratory diseases |
| 02/03/2005 | US20050026883 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026882 Such as montelukast, zafirlukast or pranlukast; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026881 Immunoglobulin E (IgE); antibody such as omalizumab; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026880 Such as cromolyn sodium or nedocromil sodium; low amounts of active agents, less prone to detrimental side effects; reducing levels of, or sensitivity to, adenosine or adenosine receptors |
| 02/03/2005 | US20050026877 Pharmaceutical compositions comprising active vitamin D compounds |
| 02/03/2005 | US20050026870 Use of bisphosphonates for the treatment of osteogenesis imperfecta |
| 02/03/2005 | US20050026851 Single dose fast dissolving azithromycin |
| 02/03/2005 | US20050026849 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| 02/03/2005 | US20050026841 Hab18g/cd147 its antagonist and application |
| 02/03/2005 | US20050026820 reducing nephrotoxicity; increased therapeutic window for the glycopeptide to allow a greater amount to be administered |
| 02/03/2005 | US20050026287 Formulation of stabilized cationic transfection agent (s) /nucleic acid particles |
| 02/03/2005 | US20050026278 RNA interference mediating small RNA molecules |
| 02/03/2005 | US20050026242 Method of complexing a protein by the use of a dispersed system and proteins thereof |
| 02/03/2005 | US20050025957 Mixture of glycosides, polyhydroxystearate and glucan; disposable wipes |
| 02/03/2005 | US20050025847 For preventing sexually transmitted disease (STD) infections which includes bisabolol; STDs such as HIV, herpes, gonorrhea, chlamydia, syphilis, and trichomoniasis |
| 02/03/2005 | US20050025846 Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| 02/03/2005 | US20050025841 Therapeutic methods using herbal compositions |
| 02/03/2005 | US20050025835 Purified polylactide such as glycolide-lactide copolymer of white color, and specified low metal ion concentration; use as implants for hydrophilic or lipophilic drugs such as octreotide or bromocriptine |
| 02/03/2005 | US20050025834 Includes an inner core of a biocompatible solid and biocompatible fluids with drug dispersed, suspended or dissolved therein, and a polymer layer covering less than 100% of the core; biocompatible solid is less soluble in physiological fluid than in the biocompatible fluid |
| 02/03/2005 | US20050025832 Methods and devices for providing prolonged drug therapy |
| 02/03/2005 | US20050025831 Release drug within the gastrointestinal tract at an ascending release rate over an extended time period; osmotic dosage form with semipermeable membrane; initial dose of drug supplied in an immediate-release overcoat; for treating hyperactivity/attention deficit with methylphenidate for example |
| 02/03/2005 | US20050025830 Polymer of given glass transition temperature whose diffusion or transport of the drug can be modified in a reversible manner by supplying energy such as ultrasonic or magnetic energy; for implantation |
| 02/03/2005 | US20050025829 Controlled drug release tablets |
| 02/03/2005 | US20050025828 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| 02/03/2005 | US20050025827 Pharmaceutical formulation for contraception and hormone-replacement therapy |
| 02/03/2005 | US20050025826 Desolventizing a mixture of a bioactive peptide or salt thereof in an organic solvent, a biodegradable polymer, and hydroxynaphthoic acid or a salt; hydroxynaphthoate salt of a bioactive peptide |
| 02/03/2005 | US20050025825 Oral dosage form which releases the drug in the small intestine for side effect reduction of nausea, vomiting, diarrhea, constipation, cramping, and bloating; improve patient compliance in treating menorrhagia |
| 02/03/2005 | US20050025824 Pulsatile release histamine H2 antagonist dosage form |
| 02/03/2005 | US20050025823 Methods of use of herbal compositions |
| 02/03/2005 | US20050025822 Method of pulmonary administration of an agent |
| 02/03/2005 | US20050025821 Lipid-comprising drug delivery complexes and methods for their production |
| 02/03/2005 | US20050025820 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| 02/03/2005 | US20050025819 Materials and methods for making improved micelle compositions |
| 02/03/2005 | US20050025818 Transdermal warfarin system |
| 02/03/2005 | US20050025817 Skin drug delivery system with pads and liquids with insoluble drugs |
| 02/03/2005 | US20050025815 Protonated/acidified nucleic acids are effective as bactericidal and/or bacteriostatic agents |
| 02/03/2005 | US20050025813 Fixing adhesive layer on sheet applying moisture retaining sheet with pad with glycerol |
| 02/03/2005 | US20050025811 Calcium carbonate granulation |
| 02/03/2005 | US20050025810 Treatment of ocular disease |
| 02/03/2005 | US20050025809 Biodegradable composition for controlled release |
| 02/03/2005 | US20050025807 Cured porous calcium phosphate material and uses thereof |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025794 Film-forming compositions and methods |
| 02/03/2005 | US20050025792 Amphiphilic surfactant with hydrophilic character that is a glyceride polyoxyethylene glycol and saturated fatty acids; or polyoxyethylated hydrogenated castor oil (Cremophor") |
| 02/03/2005 | US20050025791 Pharmaceutical compositions with improved dissolution |
| 02/03/2005 | US20050025790 Endogenous adjuvant molecules and uses thereof |
| 02/03/2005 | US20050025777 Particle-mediated delivery of antigens |
| 02/03/2005 | US20050025757 Oxygen carrier system, artificial oxygen carrier, and reducing agent |
| 02/03/2005 | US20050025742 Interferon or a gene delivery system encoding the interferon and SYN3 as delivery enhancing agent; protein or gene therapy; transurethral intravesical administration to epithelial cells; superficial bladder cancer |
| 02/03/2005 | US20050025718 Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| 02/03/2005 | US20050025717 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| 02/03/2005 | US20050025716 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| 02/03/2005 | US20050025715 Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
| 02/03/2005 | US20050025714 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 02/03/2005 | US20050025713 Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| 02/03/2005 | US20050025712 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant |
| 02/03/2005 | US20050025711 Contrast media formulations having improved biological tolerance |
| 02/03/2005 | US20050025707 Fumed silica embolic compositions |
| 02/03/2005 | US20050023386 Laboratory scale milling process |
| 02/03/2005 | DE202004013132U1 Chewable tablets with calming, anxiolytic and hypnotic actions, for medicinal, dietary or veterinary use, containing synergistic combination of herbal preparation and aromatherapeutic components |
| 02/03/2005 | DE202004009689U1 Combating stress states or nervous system or metabolic disorders, using glycine as neurotransmission modulator showing antistress, stress protective, nootropic and toxin binding actions |
| 02/03/2005 | DE10332160A1 Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform A multiparticulate pharmaceutical form comprising mucoadhesively formulated peptide or protein active ingredients, and a process for preparing the drug form |
| 02/03/2005 | DE10329087A1 Antigenhaltige Mikrosphären zur Allergietherapie Antigen-containing microspheres for allergy therapy |
| 02/03/2005 | DE10326231A1 Preparing enzyme granules, useful in nutritional, cleaning and pharmaceutical compositions, by spraying enzyme solution into gas stream containing solid particles, followed by drying and granulation |
| 02/03/2005 | DE10317079A1 Storage material for a biological, medical or homeopathic active ingredient is made from a hollow fiber or has a hollow fiber-like section |
| 02/03/2005 | CA2541373A1 Topical skin care composition containing refined peanut oil |
| 02/03/2005 | CA2536111A1 Oral compositions for treatment of diseases |
| 02/03/2005 | CA2533707A1 Treatment of lesions of the soft tissues |
| 02/03/2005 | CA2533592A1 Controlled release compositions |
| 02/03/2005 | CA2533588A1 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 02/03/2005 | CA2533577A1 Orally dissolving films |
| 02/03/2005 | CA2533551A1 Tissue adhesive sealant |
| 02/03/2005 | CA2533421A1 Use of xmp-629 for the treatment of acne |
| 02/03/2005 | CA2533358A1 Antibiotic product, use and formulation thereof |
| 02/03/2005 | CA2533330A1 Pharmaceutical preparation containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release |
| 02/03/2005 | CA2533292A1 Antibiotic product, use and formulation thereof |
| 02/03/2005 | CA2533178A1 Antibiotic product, use and formulation thereof |
| 02/03/2005 | CA2533151A1 Pharmaceutical formulations |
| 02/03/2005 | CA2533101A1 Dispersible formulation of an anti-inflammatory agent |
| 02/03/2005 | CA2532951A1 Process and machine for automated manufacture of gastro-retentive devices |
| 02/03/2005 | CA2532874A1 Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| 02/03/2005 | CA2532626A1 Particles containing an active agent in the form of a co-precipitate |
| 02/03/2005 | CA2532608A1 Orodispersible pharmaceutical composition of an antithrombotic compound |
| 02/03/2005 | CA2532310A1 Pharmaceutical compositions having a swellable coating |
| 02/03/2005 | CA2532302A1 Method for the preparation of controlled release formulations |
| 02/03/2005 | CA2531721A1 Dual drug dosage forms with improved separation of drugs |
| 02/03/2005 | CA2531637A1 Cellulosic fiber containing composition |
| 02/03/2005 | CA2531223A1 Compositions containing prodrugs of florfenicol and methods of use |
| 02/03/2005 | CA2530402A1 Delivery system for topical medications |
| 02/03/2005 | CA2530357A1 Sustained release dosage forms of anesthetics for pain management |